Certain patients have atherosclerotic/occluding #aortic disease that should not be crossed with #TAVR devices. In these patients, a #transapical approach can be safely utilized: https://t.co/sTgbakzXwN #JOCS#JCardSurg
PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but initial differences in death and stroke favoring TAVR were diminished and TAVR had increased risk of valve thrombosis. https://t.co/dOybjNzzAo
A fellow native Houstonian, the legendary Denton A. Cooley. I was fortunate to work on his pump team during my years in high school. Dr. Cooley was a great mentor and I learned many things from this incredible surgeon. @Texas_Heart
SAVR after TAVR-explant associated with 30d mortality of 19.4% & high observed-to-expected mortality ratio in analysis of the STS database. Read more: https://t.co/NoGA335XDS #AHAJournals@ShinFukuharaMD@AlexBresciaMD
I've been thinking a lot lately about how good of a surgeon we should aspire to be.
How should we measure it? Volume? Speed? How should we know when we have reached our goals?
And I think I've come across a relatively simple answer. Read it here - https://t.co/eCCCFzs5P9